A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Trial Details

NCT ID

NCT07205822

Phase

PHASE3

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Dato-DXd

Locations (sample)

• Largo, Florida, United States|27.90979,-82.78842
• Fort Wayne, Indiana, United States|41.1306,-85.12886
• Omaha, Nebraska, United States|41.25626,-95.94043
• New York, New York, United States|40.71427,-74.00597
• Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

• Participant must be ≥ 18 years (and above legal age) at the time of screening.
• Inoperable or metastatic HR-positive, HER2 IHC 0 breast cancer (per ASCO/CAP guidelines, on local laboratory results); ie, is documented as HR-posi…
• A fresh biopsy may only be omitted if not medically feasible due to documented clinical reasons, such as anatomical inaccessibility, unacceptable p…
• Progressed on and not suitable for further endocrine therapy per investigator assessment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.